BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
BREATHER Plus 临床试验设计：一项随机非劣效性试验，旨在评估短周期（用药五天，停药两天）基于多替拉韦/替诺福韦的三联抗逆转录病毒疗法 (ART) 与每日 ART 相比，在撒哈拉以南非洲地区 12 至 20 岁以下 HIV 感染青少年中，病毒学抑制的疗效、安全性和可接受性。
期刊:Contemporary Clinical Trials
影响因子:
doi:10.1016/j.cct.2025.107963
Katongole, Fredrick; Arumugam, Tiyara; Jennings, Angus; Mutata, Constantine; Ssebunya, Patrick; Wamboi, Charity; Green, Alexandra; Bwakura-Dangarembizi, Mutsa; Kityo, Cissy; Siika, Abraham; Archary, Moherndran; Jafta, Lungile; Namukwaya, Stella; Seeley, Janet; Mugerwa, Henry; Walker, Simon; Apoto, Naomi; Thomason, Margaret J; Ford, Deborah; Pett, Sarah L; Kekitiinwa, Adeodata R
